Ang Lifesciences India Ltd. · BSE:ANG
Ang Lifesciences India — Investor Presentation (August 2022)
13 slides from Ang Lifesciences India's investor presentation, August 2022
Slide 1: BSE filing cover letter for Investor Presentation August 2022
CIN No:- L24230PB2006PLC030341 ZB n GST No:- O2AAHCA5390H2ZT ANG LIFESCIENCES INDIA LIMITED PoNoAesooee ye ft ety M08 ~ 2022 To Department of Corporate Services, BSE Limited P J Towers, Dalal Street, Mumbai- 400001 Ref: BSE Security Code 540694 Sub: Investor Presentation- August 2022 Dear Sir/Madam,
Slide 2: Investor Presentation August 2022
LEE ANG LIFESCIENCES INDIA LIMITED INVESTOR PRESENTATION AUGUST 2022
Slide 3: Safe Harbor
an ANG LIFESCIENCES SAFE HARBOR INDIA LIMITED Certain statements in this document maybe forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions,local political or economic developments, technological risks, and many other fac
Slide 4: Business Highlights
N NIG BUSINESS HIGHLIGHTS ANG LIFESCIENCES INDIA LIMITED : A Listed Pharma company with a Pure-Play Formulation Model. : Strong Traction across Formulation Supply Chain comprising Government Institutional Segment, Third Party Manufacturing, AN eReie tem Cle Cre : Focused Portfolios within a Broad-ba
Slide 5: Strength by Strength
STRENGTH BY STRENGTH ANG LIFESCIENCES INDIA LIMITED Facilities Accredited by International Reg y Agencies WHO State-of-the-art Manufacturing Capabilities Internationally Benchmarked Quality and Regulatory Systems Customer Relationship through Outstanding Products and Services Pan India Presence Appr
Slide 6: Quality
a LES, QUALITY ANG LIFESCIENCES INDIA LIMITED MOH YEMEN MOH COMBODIA MOH SENEGAL MOH BOLIVIA MOH CONGO MOH GHANA MOH LIBYA QUALITY MANAGEMENT SYSTEM
Slide 7: Standalone Financial Snapshot
Ae & Standalone Financial 1 1 Snapshot an MEE INDIA LIMITED Rs. (In Lacs) Income Income from Operations 3684.16 5492.30 6766.81 7604.47 12169.98 12683.11 15427.54 34866.94 lother Income 9.46 21.03 25.02 68.72 23.27 41.97 74.62 95.15 Total Income 3693.63 5513.32 6791.82 7673.19 12193.25 12725.08 1550
Slide 8: Financial Figures - Year21 & Year22
Financial Figures - Year21 & Year22 he ANG LIFESCIENCES INDIA LIMITED Chealily Mallers FY-22 349.62 a (Cost of Sales 230.01 103.96 121% 1 Total Revenue [Employee expenses 18.32 14.35 28% Rs. 349.62 Cr |EBITDA Other expenses 35.25 66.03 21.04 15.67 68% 321% EBITDA margin 19% 10% Finance cost 7.85 3.5
Slide 9: Consolidated Figures - Q1 FY22 & Q1 FY23
a Consolidated Figures — Q122 & Q123 Be, ANG LIFESCIENCES INDIA LIMITED (healt Mlallere Q1 FY-23 Q1 FY-22 D1 FY-23 Total Revenue 73.80 ° 119.95 " -38% -38% Total Revenue Cost of Sales 47.05 73.92 36% Rs. 73 80 Cr Employee expenses 6.20 4.47 at Other expenses 8.45 12.01 -30% EBITDA 12.10 29.56 -59% E
Slide 10: Strategic Growth Path
Strategic Growth Path as ats. ANG LIFESCIENCES INDIA LIMITED 2022-23 Quali Mellere 2021-22 > Company announces the FY 22-23 as a year of consolidation in terms of sales and customer holdings with the revenue guidelines between Rs > Completed Acquisition of 350-400 Cr and EBITDA ranging 16-18%. Ind-
Slide 11: Strategic Growth Path (continued)
invest in various latest quality control equipment’s and further make available the said facility to Domestic, PICS, and EU approved Market. Convert Unit VI into dedicated Anti-Cancer Manufacturing and R&D Facility and further make available the said facility to Domestic, PICS, and EU approved Marke
Slide 12: Our Clients
OUR CLIENTS ANG LIFESCIENCES INDIA LIMITED HETERO HEALTHCARE AFMSD Ammed Forces Medical Stores Depot Haryana Medical Services Corporation Ltd. (A Govt. of Haryana Undertaking)
Slide 13: Thank You
a <> THANK Y OU see Teen INDIA LIMITED
ANG Lifesciences India — Investor Presentation (August 2022) on 6ix